Dermoi scientists have selected Neostrata due to its rich legacy in dermatologist-founded innovation spanning over four decades.
Neostrata has been a pioneer in the use of Alpha Hydroxy Acids (AHAs) and Polyhydroxy Acids in skincare that has have earned the brand recognition as a transformative force in skincare.
Neostrata products focus on surface-level skin improvements, but also target the fundamental elements of skin structure. By prioritizing both immediate and long-term benefits, Neostrata aligns with the vision of Dermoi scientists, who advocate for long-term skincare solutions.
Dermoi is proud to be an official stockist of Neostrata UK! If you have any questions about our collection of Neostrata products, please contact us.
Neostrata, a dermatologist-founded brand, carries over 40 years of dedicated experience in advancing the science of skin renewal.
Its inception in 1974 emerged from groundbreaking discoveries regarding the effects of Alpha Hydroxy Acids (AHAs) on Ichthyosis patients, offering solutions for dry, thickened, and scaly skin.
Recognizing the diverse impact of skin discoloration across various skin tones, Neostrata empowers individuals to address different forms of skin discoloration.
Their formulations, supported by clinical evidence, target skin concerns faced by aging and sun-damaged skin.
Neostrata products gradually reveal fresh skin layers within three days. Their skincare products are formulated to exfoliating surface layers of the skin to unveil smoother, renewed skin. In addition, Neostrata skincare products are formulated at optimal pH levels for heightened effectiveness.
Neostrara focuses on targeting skin's foundational elements to enhance volume and ensure sustained results over time.
Neostrata is dedicated to minimizing environmental impact of their brand. Initiatives toward sustainability include using sustainably sourced cartons and recyclable shipping boxes.
Moving forward, Neostrata plans to introduce Post-Consumer Recycled (PCR) plastic packaging, phase out virgin plastic, and aim for a minimum of 30% PCR content by 2025.
Showing all 17 results